Total Payments
$194,154
2024 Payments
$3,743
Companies
8
Transactions
46
Medicare Patients
2,721
Medicare Billing
$396,326
Payment Breakdown by Category
Research$189,993 (97.9%)
Education$2,500 (1.3%)
Travel$1,091 (0.6%)
Food & Beverage$570.66 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $189,993 | 33 | 97.9% |
| Education | $2,500 | 1 | 1.3% |
| Travel and Lodging | $1,091 | 5 | 0.6% |
| Food and Beverage | $570.66 | 7 | 0.3% |
Payments by Type
Research
$189,993
33 transactions
General
$4,161
13 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $96,846 | 4 | $0 (2021) |
| Lupin Inc. | $81,338 | 13 | $0 (2018) |
| Glenmark Pharmaceuticals Inc. | $11,808 | 16 | $0 (2018) |
| INTUITIVE SURGICAL, INC. | $3,743 | 8 | $0 (2024) |
| Ethicon Inc. | $124.40 | 1 | $0 (2021) |
| Boston Scientific Corporation | $119.56 | 1 | $0 (2023) |
| Pulmonx Corporation | $117.79 | 1 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $56.92 | 2 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,743 | 8 | INTUITIVE SURGICAL, INC. ($3,743) |
| 2023 | $176.48 | 3 | Boston Scientific Corporation ($119.56) |
| 2022 | $117.79 | 1 | Pulmonx Corporation ($117.79) |
| 2021 | $29,595 | 3 | Eli Lilly and Company ($29,471) |
| 2020 | $67,375 | 2 | Eli Lilly and Company ($67,375) |
| 2018 | $83,659 | 15 | Lupin Inc. ($81,338) |
| 2017 | $9,488 | 14 | Glenmark Pharmaceuticals Inc. ($9,488) |
All Payment Transactions
46 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Education | In-kind items and services | $2,500.00 | General |
| Category: SURGERY | ||||||
| 12/13/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $143.00 | General |
| Category: SURGERY | ||||||
| 12/13/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $16.99 | General |
| Category: SURGERY | ||||||
| 12/12/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $180.99 | General |
| Category: SURGERY | ||||||
| 12/10/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $143.00 | General |
| Category: SURGERY | ||||||
| 11/26/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $593.77 | General |
| Category: SURGERY | ||||||
| 11/26/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Travel and Lodging | In-kind items and services | $30.00 | General |
| Category: SURGERY | ||||||
| 06/18/2024 | INTUITIVE SURGICAL, INC. | Da Vinci Surgical System (Device) | Food and Beverage | In-kind items and services | $135.00 | General |
| Category: SURGERY | ||||||
| 12/27/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | Cash or cash equivalent | $28.46 | General |
| Category: Respiratory | ||||||
| 09/11/2023 | Boston Scientific Corporation | Acquire (Device) | Food and Beverage | In-kind items and services | $119.56 | General |
| Category: Acquire_ENDO | ||||||
| 08/04/2023 | AstraZeneca Pharmaceuticals LP | BREZTRI (Drug) | Food and Beverage | Cash or cash equivalent | $28.46 | General |
| Category: Respiratory | ||||||
| 09/15/2022 | Pulmonx Corporation | CHARTIS CATHETER (Device), ZEPHYR DELIVERY CATHETER, ZEPHYR ENDOBRONCHIAL VALVE | Food and Beverage | In-kind items and services | $117.79 | General |
| Category: PULMONOLOGY | ||||||
| 10/26/2021 | Ethicon Inc. | Monarch Platform (Device) | Food and Beverage | In-kind items and services | $124.40 | General |
| Category: Endo-Mechanical | ||||||
| 01/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $16,547.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | ||||||
| 01/26/2021 | Eli Lilly and Company | — | — | In-kind items and services | $12,924.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 09/29/2020 | Eli Lilly and Company | — | — | Cash or cash equivalent | $66,822.00 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 07/23/2020 | Eli Lilly and Company | — | — | In-kind items and services | $553.49 | Research |
| Study: A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | ||||||
| 06/21/2018 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $962.50 | Research |
| Study: Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | ||||||
| 05/07/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $15,750.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 04/24/2018 | Glenmark Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $1,358.00 | Research |
| Study: Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | ||||||
| 04/03/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $190.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/20/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $5,000.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/12/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $870.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 03/05/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $4,737.60 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
| 02/20/2018 | Lupin Inc. | TIOTROPIUM (Drug) | — | Cash or cash equivalent | $1,930.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS • Category: PULMONARYRESPIRATORY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, CROSSOVER, MULTICENTER CLINICAL STUDY TO ASSESS THE EFFICACY AND SAFETY OF ONCE DAILY ADMINISTRATION OF LUPIN TIOTROPIUM BROMIDE INHALATION POWDER COMPARED TO SPIRIVA HANDIHALER AND PLACEBO IN PATIENTS WITH COPD INCLUDING A 12-WEEK OPEN LABEL EXTENSION TO ASSESS INHALER ROBUSTNESS | Lupin Inc. | $81,338 | 13 |
| A RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3819253 AND LY3832479 IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS | Eli Lilly and Company | $80,299 | 3 |
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF MONO AND COMBINATION THERAPY WITH MONOCLONAL ANTIBODIES IN PARTICIPANTS WITH MILD TO MODERATE COVID-19 ILLNESS (BLAZE-4) | Eli Lilly and Company | $16,547 | 1 |
| GSP304-201 | Glenmark Pharmaceuticals Inc. | $9,488 | 14 |
| Pharmacodynamic and Pharmacokinetic Dose Ranging Study of Tiotropium Bromide Administered Via Inhalation Solution in Patients With Chronic Obstructive Pulmonary Disease (COPD) | Glenmark Pharmaceuticals Inc. | $2,321 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 12 | 485 | 724 | $139,618 | $73,153 |
| 2022 | 13 | 646 | 1,021 | $183,219 | $97,091 |
| 2021 | 15 | 835 | 1,214 | $221,178 | $116,946 |
| 2020 | 16 | 755 | 1,080 | $203,838 | $109,137 |
Total Patients
2,721
Total Services
4,039
Medicare Billing
$396,326
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 107 | 258 | $38,958 | $23,638 | 60.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 57 | 98 | $31,752 | $16,179 | 51.0% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 97 | 100 | $29,155 | $13,352 | 45.8% |
| 31652 | Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | Facility | 2023 | 33 | 33 | $10,890 | $5,374 | 49.3% |
| 31653 | Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 3 or more lymph nodes | Facility | 2023 | 27 | 27 | $9,882 | $5,028 | 50.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 25 | 68 | $7,140 | $4,085 | 57.2% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2023 | 18 | 18 | $3,852 | $1,976 | 51.3% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 12 | 12 | $2,388 | $1,203 | 50.4% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2023 | 14 | 14 | $1,778 | $910.84 | 51.2% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2023 | 65 | 65 | $1,234 | $621.44 | 50.4% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2023 | 11 | 11 | $2,189 | $564.96 | 25.8% |
| 76937 | Ultrasonic guidance for blood vessel access | Facility | 2023 | 19 | 20 | $400.00 | $220.60 | 55.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 163 | 421 | $63,723 | $33,945 | 53.3% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 110 | 112 | $32,748 | $17,437 | 53.2% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 64 | 99 | $32,174 | $17,135 | 53.3% |
| 31652 | Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 1-2 lymph nodes | Facility | 2022 | 41 | 42 | $13,866 | $7,422 | 53.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 53 | 125 | $13,131 | $7,044 | 53.6% |
| 31653 | Exam of lung airways and sampling of lymph nodes using an endoscope and ultrasound guidance, 3 or more lymph nodes | Facility | 2022 | 33 | 33 | $12,093 | $6,469 | 53.5% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 21 | 21 | $4,183 | $2,245 | 53.7% |
| 36556 | Insertion of non-tunneled central venous tube for infusion (5 years or older) | Facility | 2022 | 16 | 20 | $2,561 | $1,360 | 53.1% |
| 31624 | Irrigation and suction of lung airways to obtain cells using an endoscope | Facility | 2022 | 18 | 18 | $3,589 | $1,284 | 35.8% |
| 31500 | Emergent insertion of breathing tube into windpipe using an endoscope | Facility | 2022 | 11 | 11 | $2,354 | $1,254 | 53.3% |
| 99152 | Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | Facility | 2022 | 85 | 88 | $1,672 | $886.71 | 53.0% |
| 36620 | Insertion of artery tube for blood sampling or infusion through skin | Facility | 2022 | 11 | 11 | $726.00 | $390.27 | 53.8% |
| 76937 | Ultrasonic guidance for blood vessel access | Facility | 2022 | 20 | 20 | $400.00 | $219.03 | 54.8% |
About Dr. Brian Zeno, M.D
Dr. Brian Zeno, M.D is a Specialist healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1033149596.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Zeno, M.D has received a total of $194,154 in payments from pharmaceutical and medical device companies, with $3,743 received in 2024. These payments were reported across 46 transactions from 8 companies. The most common payment nature is "" ($189,993).
As a Medicare-enrolled provider, Zeno has provided services to 2,721 Medicare beneficiaries, totaling 4,039 services with total Medicare billing of $396,326. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Critical Care Medicine, Pulmonary Disease
- Location Columbus, OH
- Active Since 07/03/2006
- Last Updated 09/23/2024
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1033149596
Products in Payments
- TIOTROPIUM (Drug) $81,338
- Da Vinci Surgical System (Device) $3,743
- Monarch Platform (Device) $124.40
- Acquire (Device) $119.56
- CHARTIS CATHETER (Device) $117.79
- BREZTRI (Drug) $56.92
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Columbus
Dr. Lawrence Lynn, Do, DO
Specialist — Payments: $16.3M
Specialist $16.3M
Dr. Dallas Erdmann, Md, MD
Specialist — Payments: $255,768
Specialist $255,768
Raghu Kolluri, M.d, M.D
Specialist — Payments: $146,032
Specialist $146,032
Victor Dizon, Do, DO
Specialist — Payments: $137,148
Specialist $137,148
Dr. Glen Apseloff, M.d, M.D
Specialist — Payments: $74,569
Specialist $74,569
Dr. Kathleen Hawker, M.d, M.D
Specialist — Payments: $45,056
Specialist $45,056